ClinicalTrials.gg
RecruitingNCT06313697Updated Aug 22, 2024

A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2102 in Healthy Adult

A Phase 1 interventional study of GR2102 injection and placebo in Respiratory Syncytial Virus Infections, sponsored by Genrix (Shanghai) Biopharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-22.

Sponsored by Genrix (Shanghai) Biopharmaceutical Co., Ltd. (part of Chongqing Genrix Biopharmaceutical Co., Ltd) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Mar 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 30 studies in Respiratory Syncytial Virus Infections with a site in China — 8 open to participants now, 13 under way, 4 of them phase 3. Respiratory Syncytial Virus Infections · China.

Planned enrollment
13th of 25
132 · median 132
Started
2024
with 6 others
Phase 1
6 of 30
1 open now
Primary completion
2025-01
later than 1 of 12 live
Registered
16th of 30
by date

Among the 30 studies in Respiratory Syncytial Virus Infections with a site in China, this one is the 13th largest by planned enrollment of the 25 interventional ones that give a count, is one of 7 that started in 2024, is one of 6 in phase 1, reaches primary completion later than 1 of the 12 other live ones, and was the 16th registered.

Respiratory Syncytial Virus Infections

307 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 50 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

8 of the 30 studies in Respiratory Syncytial Virus Infections with a site in China are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Respiratory Syncytial Virus Infections with a site in China, or all of them as a file.
02

Study summary

the goal this clinical trail is to evaluate the safety、Pharmacokinetic and immunogenicity of GR2102 injection。 Subjects will be enrolled in different groups in sequential order, and within each group will be randomly assigned to receive either GR2102 injection or placebo administration, with each Subjects will be enrolled in only one of these groups。

Read the detailed description

This is a randomized, double-blind, placebo-controlled, single-dose administration study to evaluate the safety, tolerability, pharmacokinetics, and preliminary pharmacodynamic profile of GR2102 Injection in healthy adult Chinese subjects.

After signing the informed consent form, subjects who meet the criteria for enrollment will be entered into different groups according to the randomization number.Subjects will be enrolled in only one of these groups.

Only after the 8 subjects in the current group have completed at least 7 days of safety and tolerability observations and have been determined to be safe and tolerable, will another group of subjects be allowed to proceed to the next group .

After completion of dosing, follow-up will be at least 150 days.

03

Conditions studied

  • Respiratory Syncytial Virus Infections

Keywords

  • respiratory syncytial virus
  • RSV
  • respiratory infection
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy adult subjects
  2. Signed

Exclusion criteria

Exclusion Criteria:

  1. Signs and symptoms of upper respiratory tract infection prior to randomization
  2. Prior use of RSV vaccine or RSV antibody-based medications
  3. history of malignant tumor
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
132 participants (estimated)

Study arms

  • Experimental
    Treatment group 1

    single dose

    Biological: GR2102 injection · Biological: placebo

  • Experimental
    Treatment group 2

    single dose

    Biological: GR2102 injection · Biological: placebo

  • Experimental
    Treatment group 3

    single dose

    Biological: GR2102 injection · Biological: placebo

  • Experimental
    Treatment group 4

    single dose

    Biological: GR2102 injection · Biological: placebo

  • Experimental
    Treatment group 5

    single dose

    Biological: GR2102 injection · Biological: placebo

  • Experimental
    Treatment group 6

    single dose

    Biological: GR2102 injection · Biological: placebo

Interventions

  • BiologicalGR2102 injection

    single dose

  • Biologicalplacebo

    single dose

06

What researchers measure

Primary outcomes

  1. Adverse events

    to characterise the safety and tolerability of GR2102,including abnormal vital signs,laboratory tests,electrocardiogram and physical examination

    Time frame: 150 days post dose

Secondary outcomes

  1. Maximum Observed Serum Concentration

    Pharmacokinetic indices

    Time frame: 150 days post dose

  2. Terminal Elimination Half Life

    Pharmacokinetic indices

    Time frame: 150 days post dose

  3. anti-respiratory syncytial virus neutralizing antibodies titer levels

    indicator of immunogenicity

    Time frame: 150 days post dose

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Jan 2025, 9 months after the start.

Of 44 industry-sponsored phase 1 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's planned 9 months is above that.

Counting every sponsor, half of 57 studies reached it within 8 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2024
First posted
Mar 15, 2024
StartActual
Mar 23, 2024
Primary completionEst.
Jan 6, 2025
CompletionEst.
Dec 6, 2025
Last update
Aug 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06313697
Responsible party
Sponsor
First posted
Mar 15, 2024
Start date
Mar 23, 2024
Primary completion
Jan 6, 2025 (estimated)
Completion
Dec 6, 2025 (estimated)
Last update
Aug 22, 2024

Study contacts

wei zhao, PHD
Contact
zhao4wei@hotmail.com
15131190710
juan huang, MD
Contact
huangjuan@genrixbio.com
19301494061
wei zhao, PHD
principal investigator · The First Affiliated Hospital of Shandong First Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion